Incidence, risk factors and clinical course of thiopurine‐induced liver injury in patients with inflammatory bowel disease
Open Access
- 14 October 2005
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 22 (9) , 775-782
Abstract
Summary: Background : The incidence of thiopurine‐induced hepatotoxicity in patients with inflammatory bowel disease varies in different studies.Aims : To assess the rate of thiopurine‐induced liver toxicity in patients with inflammatory bowel disease; to determine the predictive factors and to characterize its clinical course and management.Methods : A cohort of 161 patients was prospectively followed for a median of 271 days. Hepatotoxicity was established when alanine transaminase or alkaline phosphatase plasma levels were greater than twice the upper normal limit.Results : Abnormal liver function was detected in 21 patients (13%; 95% CI: 7–18). Hepatotoxicity occurred in 16 patients (10%; 95% CI: 6–16) after a median of 85 days. In five cases, treatment was withdrawn due to hepatotoxicity. Use of corticosteroids was associated with hepatotoxicity (OR: 4.94; 95% CI: 1.01–23.98) with antitumour necrosis factor concomitant therapy showing a protective role (OR: 0.3; 95% CI: 0.1–3.1). γ‐Glutamyl transferase plasma levels at the onset of hepatotoxicity showed the best predictive value for treatment withdrawal (area under the receiver operating characteristic curve: 0.95).Conclusions : The incidence of hepatotoxicity in inflammatory bowel disease patients receiving thiopurines is relevant, mainly in patients co‐treated with corticosteroids. γ‐Glutamyl transferase plasma level is a useful biomarker in therapy withdrawal prediction.Keywords
This publication has 29 references indexed in Scilit:
- Mechanisms of Pulmonary Vascular Complications of Liver DiseaseJournal of Clinical Gastroenterology, 2005
- Increased incidence of azathioprine‐induced pancreatitis in Crohn's disease compared with other diseasesAlimentary Pharmacology & Therapeutics, 2004
- Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injuryJournal of Hepatology, 2004
- Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2002
- Drugs and SteatohepatitisSeminars in Liver Disease, 2002
- Biochemical and Cellular Mechanisms of Toxic Liver InjurySeminars in Liver Disease, 2002
- The treatment of inflammatory bowel disease with 6‐mercaptopurine or azathioprineAlimentary Pharmacology & Therapeutics, 2001
- Drug-induced liver diseasesJournal of Hepatology, 2000
- 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.Gut, 1996
- Criteria of drug-induced liver disordersJournal of Hepatology, 1990